Meeting Banner
Abstract #0128

Acute tumour response to STING activation assessed with multi-parametric MRI

Upasana Roy1, Malin Pedersen1, Carol Box1, Jessica K.R. Boult1, Antonio Rullan1, Michael Schmohl2, Sebastian Carotta3, Kevin J. Harrington1, and Simon P. Robinson1
1Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, United Kingdom, 2Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, Germany, 3RCV GmBH & Co KG, Boehringer Ingelheim, Vienna, Austria

Synopsis

Keywords: Cancer, Drug Development, Preclinical, Diffusion Imaging, RelaxometryWhilst cancer immunotherapies have shown marked and durable tumour responses in some patients, the majority derive no benefit. Strategies are being exploited to enhance tumour responses to immuno-oncology agents, including pharmacological activation of the STING pathway to create a more inflamed microenvironment. Multi-parametric MRI revealed a dose-dependent increase in murine tumour ADC in response to a STING agonist that was associated with histologically confirmed increase in tumour cell death. An acute, transient increase in tumour R2*, consistent with vascular occlusion, was also found. ADC is a sensitive early imaging biomarker of tumour response to STING agonism.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords